advertisement

---

Advances in Therapy 22

Showing records 1 to 22 | Display all abstracts in Advances in Therapy

127629 Drug Utilization, Adherence and Predictors of Drug-Changes and Discontinuation of Glaucoma Drug Therapies
Novella A
Advances in Therapy 2025; 42: 3743-3761

---

127743 A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Konstas AG
Advances in Therapy 2025; 42: 3810-3825

---

127164 Relationships Among Glaucoma, Cardiovascular Diseases, and Mortality
Quaranta L
Advances in Therapy 2025; 42: 4403-4417

---

127743 A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Garhöfer G
Advances in Therapy 2025; 42: 3810-3825

---

127164 Relationships Among Glaucoma, Cardiovascular Diseases, and Mortality
Galbussera AA; Galbussera AA
Advances in Therapy 2025; 42: 4403-4417

---

127629 Drug Utilization, Adherence and Predictors of Drug-Changes and Discontinuation of Glaucoma Drug Therapies
Quaranta L; Pasina L
Advances in Therapy 2025; 42: 3743-3761

---

127743 A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Lübke J
Advances in Therapy 2025; 42: 3810-3825

---

127164 Relationships Among Glaucoma, Cardiovascular Diseases, and Mortality
Tettamanti M
Advances in Therapy 2025; 42: 4403-4417

---

127629 Drug Utilization, Adherence and Predictors of Drug-Changes and Discontinuation of Glaucoma Drug Therapies
Galbussera AA
Advances in Therapy 2025; 42: 3743-3761

---

127743 A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Voykov B
Advances in Therapy 2025; 42: 3810-3825

---

127164 Relationships Among Glaucoma, Cardiovascular Diseases, and Mortality
Novella A
Advances in Therapy 2025; 42: 4403-4417

---

127629 Drug Utilization, Adherence and Predictors of Drug-Changes and Discontinuation of Glaucoma Drug Therapies
Galbussera AA
Advances in Therapy 2025; 42: 3743-3761

---

127743 A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Ropo A
Advances in Therapy 2025; 42: 3810-3825

---

127164 Relationships Among Glaucoma, Cardiovascular Diseases, and Mortality
Pasina L
Advances in Therapy 2025; 42: 4403-4417

---

127629 Drug Utilization, Adherence and Predictors of Drug-Changes and Discontinuation of Glaucoma Drug Therapies
Tettamanti M
Advances in Therapy 2025; 42: 3743-3761

---

127164 Relationships Among Glaucoma, Cardiovascular Diseases, and Mortality
Fortino I
Advances in Therapy 2025; 42: 4403-4417

---

127629 Drug Utilization, Adherence and Predictors of Drug-Changes and Discontinuation of Glaucoma Drug Therapies
Fortino I; Fortino I
Advances in Therapy 2025; 42: 3743-3761

---

127164 Relationships Among Glaucoma, Cardiovascular Diseases, and Mortality
Fortino I; Leoni O; Leoni O
Advances in Therapy 2025; 42: 4403-4417

---

127629 Drug Utilization, Adherence and Predictors of Drug-Changes and Discontinuation of Glaucoma Drug Therapies
Leoni O; Leoni O; Weinreb RN
Advances in Therapy 2025; 42: 3743-3761

---

127164 Relationships Among Glaucoma, Cardiovascular Diseases, and Mortality
Oddone F; Giammaria S
Advances in Therapy 2025; 42: 4403-4417

---

127629 Drug Utilization, Adherence and Predictors of Drug-Changes and Discontinuation of Glaucoma Drug Therapies
Nobili A
Advances in Therapy 2025; 42: 3743-3761

---

127164 Relationships Among Glaucoma, Cardiovascular Diseases, and Mortality
Kużniak M; Weinreb RN; Nobili A
Advances in Therapy 2025; 42: 4403-4417

---